NuSirt Biopharma, a company dedicated to improving the lives of those with chronic metabolic diseases, will be presenting two posters featuring its technology at the American Diabetes Association’s 76th Scientific Sessions. The annual event dedicated to sharing the latest advancements in diabetes research, care and treatment takes place on June 10-14, 2016, in New Orleans, Louisiana. (read more)
BioStable Science & Engineering, Inc. announced today that the first commercial implantation of its HAART 300 Aortic Annuloplasty Device was performed by Dr. Domenico Mazzitelli on Wednesday, May 11th, at the German Heart Center Munich. Additional procedures were completed on Friday, May 13th, by Professor Yeong-Hoon Choi at the University of Cologne Heart Center. These two respected heart centers were the first selected to receive the HAART 300 Aortic Annuloplasty Device as part of the limited commercial launch of the technology announced by the company in March. (read more)
A Montgomery County hospital unveiled a new technology this week that allow parents, wherever they are, to keep a close eye on their newborn in the medical center’s neonatal intensive care unit.
Holy Redeemer Hospital has installed Angel Eye Camera Systems to its NICU beds to allow parents to watch and listen to their newborn day or night, from a mobile device or computer. Access to the camera and accompanying audio system is done through a password-protected and HIPAA-compliant web site. (Read More)
Having a baby is a life-changing, joyous event. For those whose baby is born premature or with health complications, it is a time of anguish.
Advances in healthcare and neonatal intensive care units (NICUs) have improved morbidity and mortality rates, especially for premature babies, and this has led to longer stays in the hospital. A newborn may not come home for weeks or even months. New parents experience additional stress when the constraints associated with maternity leave, childcare for older siblings and transmitting infections severely limit the amount of time they can spend visiting their child in the NICU. Babies born at Maimonides Medical Center in Brooklyn, N.Y., come from culturally diverse populations with post-partum practices that sometimes restrict or even quarantine new parents after delivery so they can recuperate, creating even more obstacles for them to seeing their hospitalized newborn. (Read More)
BioStable Science & Engineering, Inc. announced today the company has received CE Mark approval for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal aortic annuloplasty ring for aortic valve repair. The company expects to begin a limited commercial launch of the product in select European heart centers in the second quarter of 2016. (Read More)
TVA Medical, Inc., a medical device company developing innovative therapies for end-stage renal disease (ESRD), today announced that its everlinQTM endoAVF System has received NUB (German Neue Untersuchungs und Behandlungsmethoden) Status 1 approval across more than 80 leading hospitals in Germany. (Read More)
Octovis’ solution is called Telle. It connects nursing staff to a remote physician, with live two-way video and real-time medical device data. Bluetooth enabled devices, like a pulse oximeter, EKG, or blood pressure cuff, are connected to a tablet that streams video between the nurse and physician while sharing data from the devices. It can integrate with EHRs, and organizations are able to use their own physicians and have access to Octovis’ partner physicians. (Read More)
TVA Medical, Inc., announced primary endpoint data from a prospective, multicenter clinical study evaluating the everlinQ™ endoAVF System. This novel medical technology creates an arteriovenous (AV) fistula for hemodialysis access in people with end-state kidney disease (ESKD) using an endovascular approach in vessels not traditionally used during surgery. (Read More)
NuSirt Biopharma today announced results from a recently completed clinical trial in patients with type 2 diabetes using its patented technology combining leucine, an essential amino acid, and low doses of metformin. The data from this trial showed comparable improvement in several glucose measures coupled with greater improvement in liver enzymes when comparing a lower dose of metformin in combination with leucine versus full dose metformin. (Read More)
NuSirt Biopharma today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its development program focused on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). NuSirt also announced the start of enrollment for its Phase 2A clinical trial targeting this disease at nine U.S. research sites. (Read More)